MedTrace Logo

Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

NCT03289273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1010

Last updated 2023-06-13

No results posted yet for this study

Summary

Observational study to evaluate, under real-world practice conditions, the safety and effectiveness of regorafenib in patients diagnosed with unresectable hepatocellular carcinoma (uHCC)

Conditions

  • Liver Neoplasms

Interventions

DRUG

Regorafenib (Stivarga, BAY73-4506)

As per the treating physicians discretion

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2022-01-31
Completion
2022-06-21

Countries

  • United States
  • Argentina
  • Austria
  • Belgium
  • Canada
  • China
  • Denmark
  • Egypt
  • France
  • Greece
  • Italy
  • Japan
  • Netherlands
  • Russia
  • Saudi Arabia
  • South Korea
  • Spain
  • Sweden
  • Taiwan
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03289273 on ClinicalTrials.gov